Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
1.
Int J Mol Sci ; 24(21)2023 Oct 27.
Artículo en Inglés | MEDLINE | ID: mdl-37958660

RESUMEN

High myopia is the most severe and pathological form of myopia. It occurs when the spherical refractive error exceeds -6.00 spherical diopters (SDs) or the axial length (AL) of the eye is greater than 26 mm. This article focuses on early-onset high myopia, an increasingly common condition that affects children under 10 years of age and can lead to other serious ocular pathologies. Through the genetic analysis of 21 families with early-onset high myopia, this study seeks to contribute to a better understanding of the role of genetics in this disease and to propose candidate genes. Whole-exome sequencing studies with a panel of genes known to be involved in the pathology were performed in families with inconclusive results: 3% of the variants found were classified as pathogenic, 6% were likely pathogenic and the remaining 91% were variants of uncertain significance. Most of the families in this study were found to have alterations in several of the proposed genes. This suggests a polygenic inheritance of the pathology due to the cumulative effect of the alterations. Further studies are needed to validate and confirm the role of these alterations in the development of early-onset high myopia and its polygenic inheritance.


Asunto(s)
Miopía , Niño , Humanos , Secuenciación del Exoma , Miopía/genética
2.
Genes (Basel) ; 14(10)2023 09 22.
Artículo en Inglés | MEDLINE | ID: mdl-37895187

RESUMEN

Keratoconus is a corneal dystrophy that is one of the main causes of corneal transplantation and for which there is currently no effective treatment for all patients. The presentation of this disease in pediatric age is associated with rapid progression, a worse prognosis and, in 15-20% of cases, the need for corneal transplantation. It is a multifactorial disease with genetic variability, which makes its genetic study difficult. Discovering new therapeutic targets is necessary to improve the quality of life of patients. In this manuscript, we present the results of whole-exome sequencing (WES) of 24 pediatric families diagnosed at the University Hospital La Paz (HULP) in Madrid. The results show an oligogenic inheritance of the disease. Genes involved in the structure, function, cell adhesion, development and repair pathways of the cornea are proposed as candidate genes for the disease. Further studies are needed to confirm the involvement of the candidate genes described in this article in the development of pediatric keratoconus.


Asunto(s)
Distrofias Hereditarias de la Córnea , Queratocono , Humanos , Niño , Queratocono/genética , Queratocono/diagnóstico , Secuenciación del Exoma , Calidad de Vida , Córnea
4.
Appl Corpus Linguistics ; 3(2): 100054, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37520765

RESUMEN

This paper sets forth a quantitative analysis of expressions of epistemicity, a category covering the expression of commitment to the information transmitted and comprising epistemic modality and evidentiality, in a corpus of 400 newspaper articles from The Guardian concerning the COVID-19 pandemic. 200 articles were written in April 2020; the other 200 were written between January and April 2022, after massive vaccination and an extraordinary increase in medical knowledge. The analysis distinguishes between a number of subtypes of epistemic expressions and three kinds of authorial voice. The results show that the April 2020 articles contain more epistemic expressions, of both weak commitment (might, perhaps, apparently…) and strong commitment (know, clearly, surely…), which suggests a greater need to distinguish the known from the unknown in this period, due to the pervasive state of uncertainty. The analysis has social implications, since it gives readers an opportunity to appreciate the careful assessments of epistemicity found in the corpus and therefore to consider the convenience of obtaining information from quality media. These social implications, together with the methodology of the analysis, contribute to the potential of the paper for pedagogical applications.

5.
Int J Mol Sci ; 24(14)2023 Jul 13.
Artículo en Inglés | MEDLINE | ID: mdl-37511188

RESUMEN

Non-syndromic pediatric cataracts are defined as opacification of the crystalline lens that occurs during the first years of life without affecting other organs. Given that this disease is one of the most frequent causes of reversible blindness in childhood, the main objective of this study was to propose new responsible gene candidates that would allow a more targeted genetic approach and expand our genetic knowledge about the disease. We present a whole exome sequencing (WES) study of 20 Spanish families with non-syndromic pediatric cataracts and a previous negative result on an ophthalmology next-generation sequencing panel. After ophthalmological evaluation and collection of peripheral blood samples from these families, WES was performed. We were able to reach a genetic diagnosis in 10% of the families analyzed and found genes that could cause pediatric cataracts in 35% of the cohort. Of the variants found, 18.2% were classified as pathogenic, 9% as likely pathogenic, and 72.8% as variants of uncertain significance. However, we did not find conclusive results in 55% of the families studied, which suggests further studies are needed. The results of this WES study allow us to propose LONP1, ACACA, TRPM1, CLIC5, HSPE1, ODF1, PIKFYVE, and CHMP4A as potential candidates to further investigate for their role in pediatric cataracts, and AQP5 and locus 2q37 as causal genes.


Asunto(s)
Catarata , Exoma , Niño , Femenino , Humanos , Masculino , Catarata/diagnóstico , Catarata/genética , Exoma/genética , Secuenciación del Exoma , Familia , Mutación , Proteínas/genética
7.
Curr Issues Mol Biol ; 45(1): 465-478, 2023 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-36661516

RESUMEN

A clinical and genetic study was conducted with pediatric patients and their relatives with optic atrophy 1 (OPA1) mutations to establish whether there is a genotype-phenotype correlation among the variants detected within and between families. Eleven children with a confirmed OPA1 mutation were identified during the study period. The main initial complaint was reduced visual acuity (VA), present in eight patients of the cohort. Eight of eleven patients had a positive family history of optic atrophy. The mean visual acuity at the start of the study was 0.40 and 0.44 LogMAR in the right and left eye, respectively. At the end of the study, the mean visual acuity was unchanged. Optical coherence tomography during the first visit showed a mean retinal nerve fiber layer thickness of 81.6 microns and 80.5 microns in the right and left eye, respectively; a mean ganglion cell layer of 52.5 and 52.4 microns, respectively, and a mean central macular thickness of 229.5 and 233.5 microns, respectively. The most common visual field defect was a centrocecal scotoma, and nine out of eleven patients showed bilateral temporal disc pallor at baseline. Sequencing of OPA1 showed seven different mutations in the eleven patients, one of which, NM_130837.3: c.1406_1407del (p.Thr469LysfsTer16), has not been previously reported. Early diagnosis of dominant optic atrophy is crucial, both for avoiding unnecessary consultations and/or treatments and for appropriate genetic counseling.

8.
Nefrologia (Engl Ed) ; 42(1): 94-98, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36153904

RESUMEN

We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection.


Asunto(s)
COVID-19 , Glomerulonefritis , Nefritis , Anticuerpos Anticitoplasma de Neutrófilos , COVID-19/complicaciones , Glomerulonefritis/tratamiento farmacológico , Glomerulonefritis/terapia , Humanos , Masculino , SARS-CoV-2
9.
Enferm. nefrol ; 25(3): 264-269, julio 2022. mapas, graf, ilus
Artículo en Español | IBECS | ID: ibc-210104

RESUMEN

Introduction:Los enfermos renales crónicos se ven obligados a tener que tomar decisiones continuamente. En este proce-so los profesionales sanitarios no suelen preguntarles cómo querrían planificar el final de sus días. En una sociedad donde la “no limitación al esfuerzo terapéutico” parece una cons-tante en nuestra práctica, el reflexionar sobre nuestros pro-pios límites podría ayudarnos en la atención a los pacientes.Objetivo: Conocer el grado de conocimiento e interés por la Planificación Anticipada de la Asistencia Sanitaria (PAAS) en profesionales que atienden a pacientes con Enfermedad Re-nal Crónica.Material y Método: Estudio observacional descriptivo trans-versal mediante cuestionario autoadministrado a sanitarios participantes voluntarios a nivel nacional. El cuestionario incluía 22 preguntas sobre conocimiento e interés sobre la planificación anticipada de la asistencia sanitaria.Resultados: Respondieron 422 profesionales: 53,3% médi-cos; 45,0% enfermeras y 1,4% técnicos en cuidados auxilia-res de enfermería. El 79,9% no conocen cuantos pacientes tienen registrado el Documento de Voluntades Anticipadas. El 63,5% han oído hablar de la Planificación Anticipada de la Asistencia Sanitaria. Un 28,7% conoce la diferencia en-tre la Planificación Anticipada de la Asistencia Sanitaria y el Documento de Voluntades Anticipadas. Un 96,2% afirma que tener esta información ayudaría a los pacientes a que estu-vieran mejor atendidos en sus últimos días. El 97,6% de los profesionales piensan que está en nuestra mano hacer algo más, a un 94,5% les gustaría recibir formación.Conclusión: Existe falta de conocimiento y un gran interés por los profesionales sanitarios sobre la Planificación Antici-pada de la Asistencia Sanitaria. (AU)


Introduction:Chronically ill kidney patients are forced to make decisions all throughout their lives. In this process, healthcare professionals often do not ask them how they would like to plan the end of their days. In today’s society “no limitation to therapeutic effort” seems to be a constant in clinical practice, so reflecting on one’s own limits could help in patient care.Objective: To determine the degree of knowledge and inte-rest in advance care planning among professionals caring for patients with chronic kidney disease.Material and Method: Cross-sectional descriptive observa-tional study using a nationwide self-administered question-naire to health care volunteers. The questionnaire included 22 questions on knowledge of and interest in advance care planning. Results:422 professionals replied: 53.3% physicians; 45.0% nurses and 1.4% auxiliary nursing care technicians. 79.9% did not know how many patients have registered an advance directives document. 63.5% had heard of advance care planning. 28.7% were aware of the difference between advance care planning and the advance directive. 96.2% affirmed that having this information would help patients to be better cared for in the last days of their life. 97.6% of the professionals thought that they could do more and 94.5% would like to receive training. Conclusion: There is a lack of knowledge and a significant inte-rest among healthcare professionals in advance care planning (AU)


Asunto(s)
Humanos , Atención a la Salud , Encuestas y Cuestionarios , Insuficiencia Renal Crónica , Pacientes
10.
Clin J Am Soc Nephrol ; 17(6): 872-876, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35551070
11.
J Invest Dermatol ; 142(8): 2238-2248.e8, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-34979109

RESUMEN

Chronic wounds represent a major health problem worldwide. Some of the available therapies based on recombinant proteins usually fail owing to the hostile environment found at the wound bed. Aptamers appear as an attractive alternative to recombinant factors owing in part to their stability, sensitivity, specificity, and low-cost production. In this study, the Cell-Systematic Evolution of Ligands by EXponential Enrichment technology was employed to generate aptamers that specifically recognize and modulate the function of the FPR2, a receptor expressed in a variety of cells involved in wound repair. Three aptamers were obtained that specifically bound to FPR2 stable transfectants generated in HaCaT cells. The targeted aptamers were shown to act as FPR2 agonists in different in vitro functional assays, including wound healing assays, and elicited a similar pattern of response to that obtained with other known FPR2 peptide agonists, such as the human LL37 cathelicidin. We have also obtained in vivo evidence for the prohealing activities of one of these FPR2 aptamers in a skin-humanized mouse model developed by us, previously shown to accurately recreate the main phases of physiological human wound repair process. In conclusion, we provide evidence of the potential therapeutic value of FPR2 aptamers for cutaneous repair.


Asunto(s)
Aptámeros de Nucleótidos , Receptores de Formil Péptido , Animales , Humanos , Ligandos , Ratones , Receptores de Formil Péptido/agonistas , Receptores de Formil Péptido/genética , Receptores de Formil Péptido/metabolismo , Receptores de Lipoxina/agonistas , Receptores de Lipoxina/genética , Receptores de Lipoxina/metabolismo , Cicatrización de Heridas
12.
Nefrología (Madrid) ; 42(1): 1-5, Ene-Feb., 2022. ilus, tab
Artículo en Español | IBECS | ID: ibc-204279

RESUMEN

Presentamos el caso de un varón afecto por neumonía SARS-CoV-2 grave, que a la vez comienza con una glomerulonefritis rápidamente progresiva p-ANCA positiva. Se comentan las distintas posibilidades terapéuticas haciendo hincapié en la idoneidad de su administración según el momento evolutivo de la infección. (AU)


We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection. (AU)


Asunto(s)
Humanos , Masculino , Nefrología , Infecciones por Coronavirus/epidemiología , Enfermedad por Anticuerpos Antimembrana Basal Glomerular/terapia , Neumonía/terapia , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/terapia , Aortitis
14.
Clin Kidney J ; 14(6): 1557-1569, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-34079618

RESUMEN

BACKGROUND: Acute kidney injury (AKI) may develop in coronavirus disease 2019 (COVID-19) patients and may be associated with a worse outcome. The aim of this study is to describe AKI incidence during the first 45 days of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Spain, its reversibility and the association with mortality. METHODS: This was an observational retrospective case-control study based on patients hospitalized between 1 March and 15 April 2020 with SARS-CoV-2 infection and AKI. Confirmed AKI cases were compared with stable kidney function patients for baseline characteristics, analytical data, treatment and renal outcome. Patients with end-stage kidney disease were excluded. RESULTS: AKI incidence was 17.22% among 3182 admitted COVID-19 patients and acute kidney disease (AKD) incidence was 6.82%. The most frequent causes of AKI were prerenal (68.8%) and sepsis (21.9%). Odds ratio (OR) for AKI was increased in patients with pre-existent hypertension [OR 2.58, 95% confidence interval (CI) 1.71-3.89] and chronic kidney disease (CKD) (OR 2.14, 95% CI 1.33-3.42) and in those with respiratory distress (OR 2.37, 95% CI 1.52-3.70). Low arterial pressure at admission increased the risk for Stage 3 AKI (OR 1.65, 95% CI 1.09-2.50). Baseline kidney function was not recovered in 45.73% of overall AKI cases and in 52.75% of AKI patients with prior CKD. Mortality was 38.5% compared with 13.4% of the overall sample population. AKI increased mortality risk at any time of hospitalization (hazard ratio 1.45, 95% CI 1.09-1.93). CONCLUSIONS: AKI is frequent in COVID-19 patients and is associated with mortality, independently of acute respiratory distress syndrome. AKD was also frequent and merits adequate follow-up.

15.
Nefrologia (Engl Ed) ; 2021 Jan 28.
Artículo en Inglés, Español | MEDLINE | ID: mdl-33781578

RESUMEN

We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection.

16.
J Leukoc Biol ; 110(5): 951-963, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-33682193

RESUMEN

As components of the innate immune response, antimicrobial peptides (AMPs) efficiently contribute to infection control and maintenance of a latent state in pulmonary tuberculosis (TB). As a therapeutic strategy, the administration of recombinant AMPs could be limited by enzymatic degradation and high production costs. Likewise, strategies based on the induction of AMPs have generated controversial results. In this study, 2 recombinant type-5 adenoviruses (Ad) expressing the human ß-defensin 3 (HßD3) or cathelicidin (LL37) were assessed in a murine pulmonary TB model. Mice infected with either a high dose of a drug-sensitive (H37Rv) or a multidrug-resistant (MDR) strain of Mycobacterium tuberculosis (Mtb) were treated with a single administration of AdHßD3, AdLL37, AdGFP (control vector expressing a green fluorescent protein), or saline solution (SS). Lungs were obtained to determine the bacterial burden, histologic damage, and cytokine expression at different time points. Mice treated with AdHßD3 or AdLL37 showed significantly lower bacterial load and pneumonia, and higher proinflammatory cytokine expression than the control groups AdGFP and SS. A synergistic therapeutic effect could be observed when first- or second-line antibiotics (ABs) were administered with adenoviral therapy in animals infected with H37Rv or MDR strains, respectively. Adenovirus-delivered AMP's administration constitutes a promising adjuvant therapy for current anti-TB drugs by enhancing a protective immune response and potentially reducing current AB regimes' duration.


Asunto(s)
Péptidos Catiónicos Antimicrobianos/administración & dosificación , Antituberculosos/administración & dosificación , Tuberculosis Pulmonar/patología , beta-Defensinas/administración & dosificación , Adenoviridae , Animales , Quimioterapia Combinada/métodos , Vectores Genéticos , Humanos , Ratones , Tuberculosis Resistente a Múltiples Medicamentos/patología , Catelicidinas
17.
Front Med (Lausanne) ; 7: 576558, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33324660

RESUMEN

Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable inherited mucocutaneous fragility disorder characterized by recurrent blisters, erosions, and wounds. Continuous blistering triggers overlapping cycles of never-ending healing and scarring commonly evolving to chronic systemic inflammation and fibrosis. The systemic treatment with allogeneic mesenchymal cells (MSC) from bone marrow has previously shown benefits in RDEB. MSC from adipose tissue (ADMSC) are easier to isolate. This is the first report on the use of systemic allogeneic ADMSC, correlating the clinical, inflammatory, and immunologic outcomes in RDEB indicating long-lasting benefits. We present the case of an RDEB patient harboring heterozygous biallelic COL7A1 gene mutations and with a diminished expression of C7. The patient presented with long-lasting refractory and painful oral ulcers distressing her quality of life. Histamine receptor antagonists, opioid analgesics, proton-pump inhibitors, and low-dose tricyclic antidepressants barely improved gastric symptoms, pain, and pruritus. Concomitantly, allogeneic ADMSC were provided as three separate intravenous injections of 106 cells/kg every 21 days. ADMSC treatment was well-tolerated. Improvements in wound healing, itch, pain and quality of life were observed, maximally at 6-9 months post-treatment, with the relief of symptoms still noticeable for up to 2 years. Remarkably, significant modifications in PBL participating in both the innate and adaptive responses, alongside regulation of levels of profibrotic factors, MCP-1/CCL2 and TGF-ß, correlated with the health improvement. This treatment might represent an alternative for non-responding patients to conventional management. It seems critical to elucidate the paracrine modulation of the immune system by MSC for their rational use in regenerative/immunoregulatory therapies.

19.
Mol Ther Methods Clin Dev ; 18: 280-290, 2020 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-32637457

RESUMEN

Current efforts to find specific genodermatoses treatments and define precise pathogenesis mechanisms require appropriate surrogate models with human cells. Although transgenic and gene knockout mouse models for several of these disorders exist, they often fail to faithfully replicate the clinical and histopathological features of the human skin condition. We have established a highly efficient method for precise deletion of critical gene sequences in primary human keratinocytes, based on CRISPR-Cas9-mediated gene editing. Using this methodology, in the present study we generated a model of Netherton syndrome by disruption of SPINK5. Gene-edited cells showed absence of LEKTI expression and were able to recapitulate a hyperkeratotic phenotype with most of the molecular hallmarks of Netherton syndrome, after grafting to immunodeficient mice and in organotypic cultures. To validate the model as a platform for therapeutic intervention, we tested an ex vivo gene therapy approach using a lentiviral vector expressing SPINK5. Re-expression of SPINK5 in an immortalized clone of SPINK5-knockout keratinocytes was capable of reverting from Netherton syndrome to a normal skin phenotype in vivo and in vitro. Our results demonstrate the feasibility of modeling genodermatoses, such as Netherton syndrome, by efficiently disrupting the causative gene to better understand its pathogenesis and to develop novel therapeutic approaches.

20.
Immunol Cell Biol ; 98(8): 626-638, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32479655

RESUMEN

Psoriasis (PS) and atopic dermatitis (AD) are common inflammatory skin diseases characterized by an imbalance in specific T-cell subsets, resulting in a specific cytokine profile in patients. Obtaining models closely resembling both pathologies along with a relevant clinical impact is crucial for the development of new therapies because of the high prevalence of these diseases. Single-gene mouse models developed until now do not fully reflect the complexity of these disorders, in part not only because of inherent differences between mice and humans but also because of the multifactorial nature of these pathologies. The skin-humanized mouse model developed by our group, based on a tissue engineering approach, has been used to test therapeutic strategies, although this methodology is still technically challenging and not widely available. The skin-humanized mouse models for PS and AD reproduce human skin phenotypes, providing valuable tools for drug development and testing in the preclinical setting. The tissue engineering approach allows the development of personalized medicine, covering the broad genotypic spectrum of these pathologies. This review highlights the main differences between available murine models focusing on the tissue-specific immunity of PS and AD. We discuss their contribution to unravel the complex pathophysiology of these diseases and to translate this knowledge into more accurate therapies.


Asunto(s)
Dermatitis Atópica , Modelos Animales de Enfermedad , Inmunidad , Psoriasis , Animales , Citocinas , Dermatitis Atópica/inmunología , Humanos , Ratones , Psoriasis/inmunología , Piel , Subgrupos de Linfocitos T
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...